The elucidation of the cell proliferation control mechanism and the infection mechanism to bladder mucosa of BCG via cAMP

1. cAMP激活剂给药对膀胱癌细胞系中BCG感染率的影响：在BCG感染人膀胱癌细胞系后，给药cAMP激活剂。BCG的感染控制在cAMP激活剂的浓度.与cAMP相关的细胞生长因子的变化的检测：与cAMP激活剂未给药组相比，与cAMP相关的细胞生长因子PKA的表达增加了约2-3倍. cAMP激活剂给药对肿瘤增殖的影响：首先，对小鼠给药BBN。8周后，将BCG和cAMP激活剂分别施用到膀胱和腹侧腔。26周后，取出膀胱并称重。cAMP激活剂未给药组和cAMP激活剂给药组的膀胱重量分别为2.68g和2.83g。与cAMP激活剂给药组相比，尽管在cAMP激活剂非给药组中显示出膀胱重量较小的趋势，但不承认显著差异。

1. Influence on BCG infection rate in bladder cancer cell line by cAMP activator administering: After BCG had been infected with the human bladder cancer cell line, the cAMP activator was administered. The infection of BCG was controlled to the density of cAMP activator.2. Examination of change in cellular growth factor related to cAMP: The expression of PKA that is the cellular growth factor related to cAMP has increased by about 2-3 times compared with cAMP activator non-administering group.3. Influence on tumor proliferation by cAMP activator administering: First, BBN was administered to the mouse. After 8 weeks, BCG and cAMP activator were administered to the bladder and ventral cavity, respectively. After 26 weeks, the bladders were removed and the bladder was weighed. The weight of the bladder was 2.68g and 2.83g in the cAMP activator non-administration group and the cAMP activator administering group respectively. A significant difference was not admitted though the tendency with a little weight of the bladder was shown in the cAMP activator non-administration group compared with the cAMP activator administering group.